JP7705351B2 - ＰＬＫ４阻害剤である（１Ｒ，２Ｓ）－（Ｅ）－２－（３－（４－（（ｃｉｓ－２，６－ジメチルモルホリノ）メチル）スチリル）－１Ｈ－イミダゾール－６－イル）－５’－メトキシスピロ［シクロプロパン－１，３’－インドリン］－２’－オンフマル酸塩のＳ４結晶形 - Google Patents

ＰＬＫ４阻害剤である（１Ｒ，２Ｓ）－（Ｅ）－２－（３－（４－（（ｃｉｓ－２，６－ジメチルモルホリノ）メチル）スチリル）－１Ｈ－イミダゾール－６－イル）－５’－メトキシスピロ［シクロプロパン－１，３’－インドリン］－２’－オンフマル酸塩のＳ４結晶形 Download PDF

Info

Publication number
JP7705351B2
JP7705351B2 JP2021562948A JP2021562948A JP7705351B2 JP 7705351 B2 JP7705351 B2 JP 7705351B2 JP 2021562948 A JP2021562948 A JP 2021562948A JP 2021562948 A JP2021562948 A JP 2021562948A JP 7705351 B2 JP7705351 B2 JP 7705351B2
Authority
JP
Japan
Prior art keywords
cancer
compound
crystal
fumaric acid
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021562948A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022530028A5 (https=
JP2022530028A (ja
Inventor
ジィー－ワン リ
マーク ロバート ブレイ
Original Assignee
ユニバーシティー ヘルス ネットワーク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバーシティー ヘルス ネットワーク filed Critical ユニバーシティー ヘルス ネットワーク
Publication of JP2022530028A publication Critical patent/JP2022530028A/ja
Publication of JP2022530028A5 publication Critical patent/JP2022530028A5/ja
Application granted granted Critical
Publication of JP7705351B2 publication Critical patent/JP7705351B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2021562948A 2019-04-24 2020-04-23 ＰＬＫ４阻害剤である（１Ｒ，２Ｓ）－（Ｅ）－２－（３－（４－（（ｃｉｓ－２，６－ジメチルモルホリノ）メチル）スチリル）－１Ｈ－イミダゾール－６－イル）－５’－メトキシスピロ［シクロプロパン－１，３’－インドリン］－２’－オンフマル酸塩のＳ４結晶形 Active JP7705351B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962837858P 2019-04-24 2019-04-24
US62/837,858 2019-04-24
PCT/CA2020/050535 WO2020215155A1 (en) 2019-04-24 2020-04-23 Crystal form s4 of the plk4 inhibitor (lr,2s)-(e)-2-(3-(4-((cis-2,6-dimethylmorpholino)methyl)styryl)- 1 h-imidazol-6- yl)-5'-methoxyspiro[cyclopropane-l,3'-indolin]-2'-one fumarate

Publications (3)

Publication Number Publication Date
JP2022530028A JP2022530028A (ja) 2022-06-27
JP2022530028A5 JP2022530028A5 (https=) 2023-04-25
JP7705351B2 true JP7705351B2 (ja) 2025-07-09

Family

ID=72940551

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021562948A Active JP7705351B2 (ja) 2019-04-24 2020-04-23 ＰＬＫ４阻害剤である（１Ｒ，２Ｓ）－（Ｅ）－２－（３－（４－（（ｃｉｓ－２，６－ジメチルモルホリノ）メチル）スチリル）－１Ｈ－イミダゾール－６－イル）－５’－メトキシスピロ［シクロプロパン－１，３’－インドリン］－２’－オンフマル酸塩のＳ４結晶形

Country Status (16)

Country Link
US (1) US12325700B2 (https=)
EP (1) EP3959209A4 (https=)
JP (1) JP7705351B2 (https=)
KR (1) KR20220004102A (https=)
CN (1) CN113966330B (https=)
AU (1) AU2020264143A1 (https=)
BR (1) BR112021021106A2 (https=)
CA (1) CA3137191A1 (https=)
EA (1) EA202192903A1 (https=)
IL (1) IL287394A (https=)
MA (1) MA55767A (https=)
MX (1) MX2021012993A (https=)
SA (1) SA521430647B1 (https=)
SG (1) SG11202111003UA (https=)
TW (1) TWI862582B (https=)
WO (1) WO2020215155A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7717842B2 (ja) 2021-05-11 2025-08-04 オリック ファーマシューティカルズ，インク． ポロ様キナーゼ４阻害剤

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016537326A (ja) 2013-10-18 2016-12-01 ユニバーシティー ヘルス ネットワーク Ｐｌｋ４阻害剤の塩および結晶形態

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7205328B2 (en) 2002-10-21 2007-04-17 Irm Llc Oxindoles with anti-HIV activity
DE102005005395A1 (de) 2005-02-03 2006-08-10 Schering Aktiengesellschaft Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel
GB0606234D0 (en) 2006-03-29 2006-05-10 Pliva Istrazivanje I Razvoj D Pharmaceutically acceptable salts and polymorphic forms
EP2205241B1 (en) 2007-09-25 2014-05-21 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
EP2235004A4 (en) 2007-12-21 2011-05-04 Univ Health Network INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL-SUBSTITUTED INDOLUND DERIVATIVES AS A KINASE-HEMMER FOR CANCER TREATMENT
ES2465971T3 (es) 2009-04-06 2014-06-09 University Health Network Inhibidores de quinasa y método para tratar cáncer con los mismos
US8586598B2 (en) 2009-04-29 2013-11-19 Nerviano Medical Sciences S.R.L. CDK inhibitor salts
SI2556071T1 (sl) 2010-04-06 2016-12-30 University Health Network Kinazni inhibitorji in njihova uporaba pri zdravljenju raka
ES2706066T3 (es) 2010-07-02 2019-03-27 Univ Health Network Procedimiento dirigido a enfermedades mutantes con PTEN y composiciones para las mismas
WO2012048411A1 (en) 2010-10-13 2012-04-19 University Health Network Plk-4 inhibitors and method of treating cancer with same
US9012464B2 (en) 2010-11-25 2015-04-21 Ratiopharm Gmbh Salts and polymorphic forms of Afatinib
US20140051679A1 (en) 2011-10-12 2014-02-20 Univeristy Health Networks Kinase inhibitors and method of treating cancer with same
WO2015054781A1 (en) 2013-10-18 2015-04-23 University Health Network Treatment for pancreatic cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016537326A (ja) 2013-10-18 2016-12-01 ユニバーシティー ヘルス ネットワーク Ｐｌｋ４阻害剤の塩および結晶形態

Also Published As

Publication number Publication date
BR112021021106A2 (pt) 2021-12-14
WO2020215155A8 (en) 2020-11-26
TW202104216A (zh) 2021-02-01
KR20220004102A (ko) 2022-01-11
TWI862582B (zh) 2024-11-21
SA521430647B1 (ar) 2024-01-27
MX2021012993A (es) 2021-12-10
MA55767A (fr) 2022-03-02
IL287394A (en) 2021-12-01
US12325700B2 (en) 2025-06-10
WO2020215155A1 (en) 2020-10-29
EP3959209A4 (en) 2022-12-28
AU2020264143A1 (en) 2021-10-28
EA202192903A1 (ru) 2022-02-09
CA3137191A1 (en) 2020-10-29
EP3959209A1 (en) 2022-03-02
SG11202111003UA (en) 2021-11-29
US20220204494A1 (en) 2022-06-30
CN113966330A (zh) 2022-01-21
JP2022530028A (ja) 2022-06-27
CN113966330B (zh) 2024-09-13

Similar Documents

Publication Publication Date Title
US11667627B2 (en) Salt and crystal forms of PLK-4 inhibitor
US10323035B2 (en) Co-crystal of a CDK inhibitor and an MEK inhibitor and process of preparation thereof
US20250171415A1 (en) Salt of substituted amino six-membered nitric heterocyclic compound, crystal form thereof, method for preparing same, and use thereof
AU2014336929A1 (en) Salt and crystal forms of PLK-4 inhibitor
US20160046615A1 (en) Novel Crystal Form of Dabrafenib Mesylate and Preparation Method Thereof
JP7705351B2 (ja) ＰＬＫ４阻害剤である（１Ｒ，２Ｓ）－（Ｅ）－２－（３－（４－（（ｃｉｓ－２，６－ジメチルモルホリノ）メチル）スチリル）－１Ｈ－イミダゾール－６－イル）－５’－メトキシスピロ［シクロプロパン－１，３’－インドリン］－２’－オンフマル酸塩のＳ４結晶形
JP2022522395A (ja) 選択的エストロゲン受容体分解剤の新規な塩
US10584130B2 (en) Solid forms of TTK inhibitor
JP2010520298A (ja) ７−［（３−クロロ−６，１１−ジヒドロ−６−メチルジベンゾ［ｃ，ｆ］［１，２］チアゼピン−１１−イル）アミノ］ヘプタン酸Ｓ，Ｓ−ジオキシドの多形相ならびにそれらの製造及び使用方法
CN105732642B (zh) 一种cdk抑制剂和mek抑制剂的共晶及其制备方法
CN105753869A (zh) 一种cdk抑制剂和mek抑制剂的共晶及其制备方法
CN105566302A (zh) 二氢吲哚酮化合物及其盐的结晶
TW202102487A (zh) N-(5-((4-乙基哌𠯤-1-基)甲基)吡啶-2-基)-5-氟-4-(3-異丙基-2-甲基-2h-吲唑-5-基)嘧啶-2-胺及其鹽的結晶與非晶型以及其製備方法與醫療用途
EA044843B1 (ru) Кристаллическая форма ингибитора plk4
CN117466898A (zh) 氨基吡唑并嘧啶化合物的晶体
WO2023006057A1 (zh) 氨基吡唑并嘧啶化合物的晶体
WO2016169030A1 (zh) 吡啶胺化合物的富马酸盐及其晶体
HK1227404B (en) Salt and crystal forms of plk-4 inhibitor
HK1227404A1 (en) Salt and crystal forms of plk-4 inhibitor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230417

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230417

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230529

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240905

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250326

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250529

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250627

R150 Certificate of patent or registration of utility model

Ref document number: 7705351

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150